



# "Improving treatments for Atrial Fibrillation, a challenge for the welfare system"

#### Webinar event

About 6 M people in Europe suffer from Atrial Fibrillation (AF), the most common cardiac arrhythmia, a heart condition that causes an irregular heart rate. AF doubles the risk of all-cause mortality and a worsened Quality of Life. By 2050, 2% of the world population will be affected by this condition. The highly effective treatment of AF is ablation. However, a precise diagnosis comes first. Only with a detailed diagnosis can we stratify AF patients precisely and give them the best treatment.

This webinar is the first event about AF which brings together investigators, policy makers, industry and patients associations to discuss about the AF. Civil society has the power to influence behaviour and decision making by individuals and by organisations and institutions that are involved.

# **Objectives**

- ✓ Discuss the relevance of stratifying patients to obtain a better diagnosis of AF.
- ✓ Present to the audience the different projects and their aims.
- ✓ Establish future collaboration channels between the participants.

#### Addressed to

- ✓ Researchers and clinicians;
- ✓ Policy makers and industry;
- ✓ General public and patients associations.

## Where and When

- √ Virtual event
- ✓ 29<sup>th</sup> October 2020, from 15h to 16:30h (CET)

## Subscription

- ✓ Free subscription but mandatory (<u>here</u>).
- ✓ Deadline to subscription: 26th October 2020.

## **Programme**

## Welcome and opening

15:00-15:05

María Guillem, Coordinator of Personalize-AF project

## **Session A** Projects presentation and Roundtable

15:05-16:25

Speaker 1: Trudie Lobban, MBE – Arrhythmia Alliance & AF Association

Speaker 2: Felipe Atienza, Activity leader of AF-FINE project

Speaker 3: Daniel Engler, AFFECT-EU project

**Debate** 

Closure 16:25-16:30

María Guillem, Coordinator of Personalize-AF project

#### Co-Organizers:









# **Curriculum of Speakers**

#### **María Guillem**



Maria S. Guillem, Master's in Biomedical Engineering (Northwestern University, NU, 2006) and PhD in Electronics Engineering (Universitat Politècnica de València, UPV, 2009) is the Deputy Director of ITACA Research Institute at UPV and head of the Cardiac Oriented Research Laboratory.

She was a Fulbright fellow at NU and currently is an Associate Professor at the Electronics Engineering Department at UPV. Dr. Guillem is co-author of 40 international scientific research papers,

more than 100 conference papers, 3 patents, and has participated in 40 national/international research projects, 7 of them as PI. Her research interests include the development of medical instrumentation and signal processing for the diagnosis and treatment of cardiac diseases. She participates in the Executive Board of the Consortium for Electrocardiographic imaging and the Board of Directors of Computing in Cardiology.

## **Felipe Atienza**



Felipe Atienza is a Doctor of Medicine from the University of Valencia, he made his training as a cardiologist at the Hospital General Universitario de Valencia and completed his pre- and post-doctoral training at various universities in Gran

Britain and the United States. In 2001, he completed his Master's Degree for the Sub-specialization in Cardiac Electrophysiology from the University Complutense de Madrid. Since 2002 he has been working in the Cardiology of the Hospital General Universitario

Gregorio Marañón in Madrid, where he is Clinical Chief, Research and Training Coordinator and Professor Associate of the Department of Medicine of the Universidad Complutense de Madrid. He has given more than 60 invited lectures, is a senior researcher of studies derived from national and international competitive funding, and is co-authored over 100 articles published in JCR, with 4435 citations, an H- Index 31 and has directed 4 PhDs. His main areas of research are are atrial fibrillation and sudden death. In the area of transference, it is co-inventor on 2 patents.

#### **Trudie Lobban**



Trudie Lobban MBE, FRCP Edin, established STARS (Syncope Trust and Reflex anoxic Seizures) charity following the diagnosis of her daughter with RAS and at the request of her paediatric neurologist in 1993. Trudie is an expert patient representative and advocate who has led the establishment of over 40 heart rhythm organisations worldwide in the past 27 years; working collaboratively with key partners of all backgrounds and disciplines to improve the diagnosis, treatment and care of both children and adults affected by cardiac arrhythmias and sudden cardiac death.

### Co-Organizers:









Trudie was instrumental in organising and campaigning to introduce new standards in the UK for arrhythmias and sudden cardiac death.

Trudie went on to establish the Arrhythmia Alliance – The Heart Rhythm Charity®: working together to improve the diagnosis, treatment and quality of life for all those affected by arrhythmias. In 2007, due to the high demand for information and resources on atrial fibrillation, Trudie launched the AF Association. She was recognized for her Services to Healthcare when being made a Member of the British Empire (MBE) in the Queen's Birthday Honours list in 2009. She has been Runner-Up for the Lifetime Achievement Award, Directory of Social Change in 2014 and an become Honorary Fellow of the Royal College of Physicians (FRCP) (Edin) in 2013.

# **Daniel Engler**

Daniel Engler is a health scientist and project manager and has been actively engaged in the submission and implementation of European and national grants since 2015 at the Research and Transfer Centre HAW Hamburg (FTZ-ALS) and UKE. He graduated from University Furtwangen/University of Maastricht and the University of Applied Sciences Hamburg. He received BSc and MSc degrees in health sciences/European public health.

Daniel Engler has been active in the research project management field since 2015 for several national and H2020 EC funded projects (AFFECT-EU, MMAF, EARTHS, AFRINET). At present, he is being appointed as a heath scientist and project manager for the University Heart Center Hamburg and being involved in managing local and international research projects in the field of cardiovascular disease.





